(c) 2024 PillSync.com

24 HR Morphine Sulfate 45 MG Extended Release Oral Capsule

1 INDICATIONS AND USAGE Morphine Sulfate Extended-Release Capsules are indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations, [see Warnings and Precautions ( 5.1 )] , reserve Morphine Sulfate Extended-Release Capsules for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Morphine Sulfate Extended-Release Capsules are not indicated as an as-needed (prn) analgesic. Morphine Sulfate Extended-Release Capsules are an opioid agonist indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations, reserve Morphine Sulfate Extended-Release Capsules for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Morphine Sulfate Extended-Release Capsules are not indicated as an as-needed (prn) analgesic. ( 1 )

actavis pharma, inc.


4 years ago CAPSULE PURPLE logo 3116 24 HR Morphine Sulfate 45 MG Extended Release Oral Capsule

CAPSULE PURPLE logo 3116

16 HOW SUPPLIED/STORAGE AND HANDLING

MORPHINE SULFATE Extended-Release capsules, USP (Once Daily) are available as follows: 30 mg – Size 3 capsule with dark blue opaque cap and body, printed with and 3090 on both the cap and body in black ink. capsules are supplied in bottles of 100 (NDC 0228-3090-11). 45 mg – Size 3 capsule with violet opaque cap and body, printed with and 3116 on both the cap and body in black ink. capsules are supplied in bottles of 100 (NDC 0228-3116-11). 60 mg – Size 2 capsule with light green opaque cap and body, printed with and 3091 on both the cap and body in black ink. capsules are supplied in bottles of 100 (NDC 0228-3091-11). 75 mg – Size 1 capsule with brown opaque cap and body, printed with and 3117 on both the cap and body in black ink. capsules are supplied in bottles of 100 (NDC 0228-3117-11). 90 mg – Size 1 capsule with green opaque cap and body, printed with and 3092 on both the cap and body in black ink. capsules are supplied in bottles of 100 (NDC 0228-3092-11). 120 mg – Size 0 capsule with light blue opaque cap and body, printed with and 3093 on both the cap and body in black ink. capsules are supplied in bottles of 100 (NDC 0228-3093-11). Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light and moisture. Dispense in a tight, light-resistant container as defined in USP. Store

MORPHINE SULFATE Extended-Release capsules securely and dispose of properly [see Patient Counseling Information ( 17 )] . capsule image capsule image capsule image capsule image capsule image capsule image


More pills like CAPSULE logo 3116












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site